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a  b  s  t  r  a  c  t
There  is a need  for  more  efﬁcient  vaccines  to combat  viral  diseases  of Atlantic  salmon  and  other  farmed
ﬁsh.  DNA  vaccines  are  highly  effective  against  salmonid  rhabdoviruses,  but have  shown  less  effect  against
other  viruses.  In the  present  work  we have  studied  if type  I IFNs  might  be  used  as adjuvants  in  ﬁsh
DNA  vaccines.  For  this  purpose  we chose  a DNA  vaccine  model  based  on the  hemagglutinin-esterase
(HE) gene  of infectious  salmon  anemia  virus  (ISAV)  as  antigen.  Salmon  presmolts  were  injected  with  a
plasmid  encoding  HE  alone  or together  with  a plasmid  encoding  Atlantic  salmon  type  I IFN  (IFNa1,  IFNb
or  IFNc).  Sera  were  harvested  after  7–10 weeks  for measurements  of  antibody  against  ISAV  and  the  ﬁsh
were  challenged  with  ISAV  to measure  protective  effects  of  the  vaccines.  The  results  showed  that  all
three  IFN  plasmids  delivered  together  with  HE plasmid  potently  enhanced  protection  of  salmon  against
ISAV  mediated  mortality  and  stimulated  an increase  in  IgM antibodies  against  the virus.  In  contrast,tlantic salmon
ntibody
emagglutinin-esterase
HE  plasmid  alone  gave  low  antibody  titers  and  a minor  protection  against  ISAV.  This  demonstrates  that
type I IFNs  stimulate  adaptive  immune  responses  in  ﬁsh,  which  may  be  a beneﬁt also  in  other  ﬁsh  DNA
vaccines.  Quantitative  RT-PCR  studies  showed  that  the salmon  IFNs  caused  an  increased  inﬂux of B-cells
and  cytotoxic  T-cells  at the  muscle  injection  site,  which  may  in  part explain  the  adjuvant  effect  of the
IFNs.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The large increase in ﬁsh farming in the world requires ade-
uate control of virus diseases, which is a major problem in the
ndustry [1]. The orthomyxovirus infectious salmon anemia virus
ISAV) is an example of a virus that causes serious disease of farmed
tlantic salmon in Europe, Chile and North America. In 2007, ISAV
aused an outbreak in Chile that had devastating effects on the
ountry’s salmon farming industry [1]. While most bacterial dis-
ases of farmed salmon have been defeated by highly protective
accines, virus vaccines based on formalin inactivated viruses or
ecombinant viral proteins have been unable to efﬁciently combat
irus diseases [2]. DNA vaccines seemed to be more promising since
hey provide a high level of protection against the rhabdoviruses
iral hemorrhagic septicaemia virus and infectious hematopoietic
Abbreviations: IFN, interferon; ISAV, infectious salmon anemia virus; IPNV, infec-
ious pancreatic necrosis virus; HE, hemagglutinin-esterase; i.m., intramuscular; i.p.,
ntraperitoneally; PBS, phosphate-buffered saline; RT-qPCR, reverse transcription
uantitative PCR.
∗ Corresponding author. Tel.: +47 77644487; fax: +47 77644900.
E-mail address: borre.robertsen@uit.no (B. Robertsen).
ttp://dx.doi.org/10.1016/j.vaccine.2015.03.093
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
virus in salmonids [3]. However, DNA vaccines against ISAV and
infectious pancreatic necrosis virus have shown inferior protec-
tive effects compared to rhadoviral DNA vaccines [4]. In this work
we decided to study if type I IFNs (IFN-I) might be used as adju-
vants in DNA vaccines against virus in ﬁsh since it is known that
IFN-I enhance the adaptive immune response in mammals [5]. The
adjuvant effect of IFN-I in mammals has been linked to direct stim-
ulation of B cells T cells and dendritic cells [6,7].
Atlantic salmon possesses at least four IFN-I subtypes, named
IFNa, IFNb, IFNc and IFNd, which have only 22 to 37% amino acid
sequence identity and show major differences in cellular expres-
sion and antiviral activity [8–10]. IFNa1 and IFNc induce antiviral
activity against IPNV and ISAV, while IFNb is less active and IFNd
show no antiviral activity [9,11]. In this work we have tested the
adjuvant effect of IFNa1, IFNb and IFNc in a DNA vaccine model,
using ISAV hemagglutinin-esterase (HE) as antigen [12]. Atlantic
salmon presmolts were injected with plasmid expressing HE alone
or together with a plasmid expressing IFN, and protection and anti-
body levels against ISAV were the measured 7–10 weeks later. The
results showed that all three IFN plasmids delivered together with
HE plasmid potently enhanced protection and antibody production
against ISAV. In contrast, HE plasmid alone gave low antibody titers
and a minor protection against ISAV. RT-qPCR of immune genes at
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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he muscle injection site suggested that the IFNs attracted B cells
nd cytotoxic T cells.
. Materials and methods
.1. Fish
Atlantic salmon (Salmo salar L.) presmolts (30–45 g) were
btained, labeled and kept in 300 l tanks at 10 ◦C as described [13].
ll handling of ﬁsh was in accordance with the Norwegian “Regu-
ation on Animal Experimentation” and all ﬁsh experiments were
ubmitted to and approved by the Norwegian Animal Research
uthority (NARA) before initiation.
.2. Virus
The ISAV Glesvaer/2/90 isolate was obtained and grown as
escribed [11]. Virus titers were calculated by the TCID50 method
14].
.3. Plasmids used for intramuscular injection
Plasmids encoding Atlantic salmon IFNa1, IFNb and IFNc were
vailable from a previous study [9] and were sub-cloned into the
cDNA3.3-TOPO vector (Invitrogen) downstream of the CMV  pro-
oter. In this work we named these plasmids pIFNa, pIFNb and
IFNc. A religated pcDNA3.3 plasmid without insert was  used as
egative control. The ISAV hemagglutinin-esterase (HE) expres-
ion vector was obtained from professor Espen Rimstad, Norwegian
chool of Veterinary Science, Oslo, and consists of ISAV HE fused
o the N-terminus of EGFP in the eukaryotic expression plasmid
EGFP-N1 [12]. The pEGFP-N1 plasmid was used as negative con-
rol. In the present work we named these plasmids pHE and pEGFP,
espectively. Plasmids were transformed and grown in One Shot
OP10 Escherichia coli (Invitrogen) and puriﬁed by EndoFree plas-
id  puriﬁcation kit (Qiagen).
.4. DNA vaccination and challenge
Presmolt salmon were injected i.m. approximately 1 cm below
he dorsal ﬁn with one or two plasmids (15 g each) in 50 l sterile
BS at pH 7.4 or with PBS only in three different tanks as described in
ig. 1A (Tank 1), Fig. 1B (Tank 2) and Fig. 1C (Tank 3), respectively.
n Fig. 1A and B tanks, the ﬁsh were kept for 7 weeks and then
nfected by i.p. injection with 104 ISAV. In Fig. 1C tank, the ﬁsh were
hallenged 8 weeks post vaccination by addition of 20% “shedder”
resmolts, which had been injected i.p. with 105 ISAV. Mortality
as recorded daily until day 32 in Tank 1 and Tank 2, and until day
2 in Tank 3.
.5. Quantitation of virus in head kidney of survival ﬁsh from the
ohabitation challenge
ISAV was quantitated by RT-qPCR of segment 8 in head kidney
rom survival ﬁsh in the cohabitation challenge trial 62 days after
ddition of shedder ﬁsh (experiment 1C). Head kidneys were kept in
NAlater (Ambion) and total RNA was isolated by Qiagen RNeasy
ini kit (Qiagen). One g RNA was used for cDNA synthesis by
uantiTect Reverse Transcription Kit (Qiagen). qPCR was  carried
ut using ISAV segment 8 primers as described [15]. Elongation
actor 1B (EF1B) was used as a reference gene [16]. ISAV seg-
ent 8 cloned into the pCR-Blunt II TOPO plasmid (Invitrogen) was
sed for calculating ISAV segment copy numbers per 0.1 g RNA in
he head kidney samples by preparing a standard curve of plasmid
opy numbers versus CT-values as described in the manual from
he manufacturer of the 7500 FAST Real-Time PCR system (Applied3 (2015) 2442–2448 2443
Biosystems), which was  used for qPCR. Based on this, virus copy
numbers in ﬁsh was plotted as a column using box and whiskers,
and signiﬁcant differences were analyzed by Kruskal–Wallis test
and post hoc Dunn’s multiple comparisons test method (GraphPad
Prism vision 6.01 for Windows, San Diego).
2.6. Measurement of antibody response by ELISA
ISAV-speciﬁc IgM antibodies in salmon sera were measured by
ELISA using ISAV as antigen. ISAV4 was propagated in ASK cells and
puriﬁed by ultracentrifugation as described [17] using a 15 to 65%
(wt/vol) sucrose gradient. The virus fraction was harvested and the
total protein concentration was measured with BCA protein assay
kit (Pierce, Thermo Science).
Microtiter plates (Immuno-Plate Maxisorp, Nunc) were coated
overnight at 4 ◦C with ISAV corresponding to 200 ng protein in
100 l 0.1 M sodium carbonate buffer (pH 9.6) in each well. The
plates were then washed and blocked with 5% dry skim milk in
TBST buffer (50 mM Tris–HCl, 150 mM NaCl, 0.1% Tween 20, pH
7.6). Fish sera were two-fold diluted in TBST buffer from 1:50 to
1:12,800 fold dilution and 100 l of each dilution was added to each
antigen-coated well and incubated over night at 4 ◦C. Monoclonal
mouse anti-salmon Ig (H) (Clone IPA3D1, mouse IgG1, Cedarlane
labs) (1:300) and subsequently peroxidase conjugated polyclonal
goat anti-mouse Ig (Invitrogen) (1:2000) were added in TBST buffer
and incubated at room temperature for 2 h. One hundred micro liter
TMB  substrate (Thermo Scientiﬁc Pierce) was  added and reacted for
10 min  when the reactions were stopped with 100 l 2 M H2SO4.
Optical density was measured at 450 nm.  Sera from ISAV-infected
ﬁsh were used as the positive control. All sera were tested in dupli-
cates and antibody titer was determined as the highest dilution
whose OD450 was above the mean OD450 plus 2 standard devia-
tions of the same serum dilution from ﬁsh injected with control
plasmids or from ﬁsh injected with HEK293 cell supernatant for
oil-formulated vaccine experiment. The antibody titer of each ﬁsh
was plotted as a column using scatter graph (GraphPad Prism vision
6.01 for Windows, San Diego). If the titer was  lower than its starting
dilution of 1:50, the titer was ascribed a value of 25 when calcu-
lating the mean titer. The mean of each group was printed above
its column. Signiﬁcant differences of the mean ranks between dif-
ferent columns were analysis by Kruskal–Wallis test and post hoc
Dunn’s multiple comparisons test method (GraphPad Prism vision
6.01 for Windows, San Diego).
2.7. Virus neutralizing activity
ISAV neutralizing activity in sera was  tested as described by
Lauscher [16].
2.8. Vaccination of ﬁsh with an oil-formulated vaccine containing
inactivated ISAV with or without recombinant IFNc
Recombinant IFNc (rIFNc) was prepared in HEK293 as described
[9]. ISAV was grown in ASK cells and after freezing and thaw-
ing, virus in the cell lysates were inactivated with 0.1% formalin
at room temperature for 3 days. After inactivation, formalin was
removed by dialysis against PBS. The antigenic content of the
inactivated virus was  measured by hemagglutination assay [18].
Each vaccine dose consisted of 0.1 ml  containing 8 hemaggluti-
nation units of inactivated ISAV (WVV) alone or combined with
0.1 ml  HEK293 medium in oil adjuvant or WVV  combined with
3.6 × 104 unit rIFNc in oil adjuvant. Control vaccines contained
HEK293 medium or rIFNc in oil adjuvant. The vaccines were formu-
lated as a water-in-oil emulsion using MontanideTM ISA 763A VG
(Seppic) with an adjuvant/antigen ratio of 70/30 (weight/weight).
Groups of Atlantic salmon presmolts (65 ﬁsh per group,
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Fig. 1. Survival plots and virus quantitation for salmon vaccinated by intramuscular injection of ISAV hemagglutinin esterase plasmid (pHE) in combination with IFN plasmids
after  challenge with ISAV. (A) Fish challenged by i.p. injection of ISAV at 7 weeks after vaccination with pHE in combination with pIFNa1, pIFNc or pcDNA 3.3 or with pEGFP
in  combination with IFN plasmids or pcDNA3.3 (n = 50). (B) Fish challenged by i.p. injection of ISAV at 7 weeks after vaccination with pHE in combination with pIFNb or
pcDNA 3.3 or with pEGFP in combination with pIFNb or pcDNA3.3 (n = 50). (C) Fish challenged by addition of ISAV infected cohabitant ﬁsh 8 weeks after vaccination with
pHE  in combination with pIFNa1, pIFNc or pcDNA 3.3 plasmids or with pEGFP in combination with IFN plasmids or pcDNA3.3 (n = 50). pcDNA3.3 is the plasmid control for
IFN  plasmids while pEGFP is the plasmid control for the HE plasmid. (D) Quantitation of ISAV in head kidney of surviving ﬁsh from the cohabitation challenge in (C) At day 62
after  addition of infected cohabitants in the vaccine experiment described in (C) head kidneys were sampled from 8 survival ﬁsh in each of the vaccine groups. ISAV levels in
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igniﬁcant differences between pIFNs + HE and pcDNA3.3 + HE groups are indicated
verage weight 30 g) were anesthetized with 0.005% benzocaine
nd tagged by alcian blue tattooing. Each ﬁsh was  injected i.p.
ith a vaccine dose of 0.1 ml.  All groups were kept in one 900 l
ank in fresh water of 10 ◦C. Group 1 ﬁsh were injected with
VV only, Group 2 ﬁsh were injected with HEK293 cell super-
atant alone, Group 3 ﬁsh were injected with WVV  together with
EK293 supernatant, Group 4 ﬁsh were injected with rIFNc alone
nd Group 5 ﬁsh were injected with WVV  together with rIFNc. Eight
eeks post vaccination, sera were sampled from 15 ﬁsh before
ohabitant infection by addition of 20% shedder ﬁsh, which were
njected i.p. with 0.1 ml  ISAV (105 TCID50) and placed into the same
ank. Mortality was recorded daily. The experiment was  ended at
ay 62 p.i. when the mortality of the control group had reached
pproximately 70%.
.9. Reverse transcription quantitative PCR (RT-qPCR)
Muscle samples from plasmid injection sites were collected in
NAlater (Ambion) and RNA isolation, cDNA synthesis and real
ime PCR were performed as described previously [13]. The rela-
ive expression of each gene was calculated by the Ct method
19] using EF1B as a reference gene [16]. Data were calculated
rom triplicates of ﬁve samples in each group, and expressed as
ean ± standard errors. The primers used in RT-qPCR are listed
n Table 1. Gene transcripts were compared using an unpaired
tudent’s t-test and considered as statistically signiﬁcant at
 ≤ 0.05. was converted to virus particles as described in Materials and methods. Statistical
asterisks, * p < 0.05, ** p < 0.01, *** p < 0.001 or **** p < 0.0001.
3. Results
3.1. IFNs increase the protective effect of HE against challenge
with ISAV
To test if the IFNa1, IFNb or IFNc might increase the protective
effect of HE against ISAV infection of salmon, ﬁsh were injected
with various combinations of IFN plasmids and HE plasmids or
the respective control plasmids, kept for 7 or 8 weeks and then
challenged by ISAV (Fig. 1). In the 7 week vaccination experiment,
the effects of pIFNa1 and pIFNc were studied in one tank (Fig. 1A)
and the effect of the pIFNb in another tank (Fig. 1B). 32 days after
injection of ISAV, ﬁsh injected with control plasmids showed high
mortality in both tanks (<5% survival). In tank 1, ﬁsh injected with
pHE and pIFNa1 showed signiﬁcantly higher protection (64% sur-
vival) than ﬁsh injected with pHE and pcDNA3.3 (28% survival) or
pIFNa1 and pEGFP (10% survival). As expected [13], pIFNc also gave
signiﬁcant protection (55% survival), but ﬁsh injected with pHE
together with pIFNc obtained even higher protection (74% survival).
In tank 2, survival of ﬁsh injected with pHE together with pIFNb was
much higher (76%) than of ﬁsh injected with pIFNb and pEGFP (20%)
or with pHE and pcDNA3.3 (14%).
In the 8 week vaccination experiment, the adjuvant effects of
pIFNa1 and pIFNc were compared by cohabitation challenge with
ISAV injected ﬁsh, which is similar to natural infection (Fig. 1C). The
mortality of ﬁsh injected with pIFNa1 or control plasmids again
developed similarly (36 and 30% survival) while pHE gave some
C.-J. Chang et al. / Vaccine 33 (2015) 2442–2448 2445
Table  1
Primers used for qPCR of immune genes.
Gene name Accession no. Forward primer (5′–3′) Reverse primer (5′–3′)
IgM Y12457.1 TGAGGAGAACTGTGGGCTACACT TGTTAATGACCACTGAATGTGCAT
IgT  ACX50290 CAACACTGACTGGAACAACAAGGT CGTCAGCGGTTCTGTTTTGGA
CD3  epsilon NM 001123622 CTCAGGGCTCGGAAGAAGTCT GGCCACGGCCTGCTGA
CD4  EU409794.1 GAGTACACCTGCGCTGTGGA GGTTGACCTCCTGACCTACAA
CD8a  NM 001123583.1 CGTCTACAGCTGTGCATCAATCAA GGCTGTGGTCATTGGTGTAGTC
CD83  DQ339141.1 GCACCTGTAGGAGAGCAGAACC TCCCTTTCTTCTGATTGGTCTGT
CD86  DW580717.1 TAGACCACACACAGGGAACAATG ATTGAGATGTATGTTCTTGTCGTCG
MHC  II ABX44766.1 ATGGTGGAGCACATCAGCC CTCAGCCTCAGGCAGGGAC
MHC  I JN561338.1 GAAGAGCACTCTGATGAGGACAG CACCATGACTCCACTGGGGTAG
Perforin 1-1 ACI33854.1 CGTTGTCACCATGGAACGTAA GCCTCTGAGCCTGTCTATCCA
Perforin 1-2 ACI33201.1 CTCCATCGCTCCAGTGAGTCT TGGTTCCAGCGAGCATAAACT
AGG
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pGranzyme A NM001141037.1 GCTA
IFN  gamma  AY795563.1 AAG
EF1a  BG933853 TGCC
rotection (60% survival). In contrast, pIFNa1 plus pHE, pIFNc plus
E or IFNc alone gave much higher protection (94%, 90% and 82%
urvival), which were signiﬁcantly higher than in the pHE group.
irus copy numbers in head kidney of survival ﬁsh was  estimated
y RT-qPCR (Fig. 1D). Fish injected with control plasmids or pIFNa
lone contained the highest virus numbers, which was  not signiﬁ-
antly different from ﬁsh injected with pHE alone. As expected, ﬁsh
njected pIFNa + pHE or pIFNc + pHE contained signiﬁcantly lower
irus numbers. Taken together, these results demonstrate strong
djuvant effects of IFNa and IFNb plasmids when administrated
ogether with the HE plasmid. The adjuvant effect of pIFNc was
ess clear from these challenge experiments because pIFNc alone
rovides such a high level of protection against ISAV infection [13].
.2. Type I IFNs enhance the antibody response against ISAV
To test whether IFNs stimulate the antibody response of Atlantic
almon against ISAV HE antigen, the ﬁsh were injected i.m. with
HE together with either pIFNa, pIFNb, or pIFNc or with pcDNA3.3
ithout insert. Controls were IFN plasmids injected together with
EGFP. Ten weeks later, sera were harvested and IgM antibody
esponses were measured by ELISA using whole ISAV as coat-
ng antigen (Fig. 2). The results showed that antibody titers of
era from ﬁsh injected with pEGFP together with IFN-plasmids
ig. 2. Anti-ISAV antibody titers in serum of ﬁsh 10 weeks after i.m. injection of
ifferent combinations of HE and IFN plasmids. Fish immunized by injection with
cDNA3.3, pIFNa1, pIFNb or pIFNc together with pHE or by injection with pIFNa1,
IFNb or pIFNc together with pEGFP (control for HE) or by injection with pcDNA3.3
nd pEGFP. IgM antibody responses were measured by ELISA using puriﬁed ISAV
s  coating antigen. Antibody titer was determined as the highest dilution whose
D450 was above the mean OD450 plus 2 standard deviations of the same serum dilu-
ion from ﬁsh injected with pcDNA3.3 and pEGFP (n = 8). Numbers above columns
how mean antibody titers. Statistical signiﬁcant difference between pIFNs + HE and
cDNA3.3 + HE (p < 0.05) is indicated with an asterisk.GGAGTCGTGTCCTT CAATGACTTCCGCATGGTTTT
GTGATGTGTTTCTG TGTACTGAGCGGCATTACTCC
CAGGATGTCTAC CACGGCCCACAGGTACTG
or the pcDNA3.3 control plasmid were similar and ranged from
72 to 462. The mean antibody titer of sera from ﬁsh injected
with the pHE together with pcDNA3.3 was  also only 412. In con-
trast, the mean antibody titers of ﬁsh injected with pIFNa + pHE,
pIFNb + pHE or pIFNc + pHE plasmids were 9603, 8803 and 9600,
respectively, which were signiﬁcantly higher than antibody titers
from ﬁsh injected with pHE together with pcDNA3.3 (p < 0.05).
This showed that all three IFNs enhanced the adaptive humoral
immune response against ISAV HE to a similar extent and conﬁrmed
the adjuvant activity of type I IFN in salmon. ISAV neutraliz-
ing activities in the sera were measured, but showed low titers.
There were no signiﬁcant differences between ﬁsh vaccinated with
pcDNA3.3 + pEGFP and ﬁsh vaccinated with pHE with or without an
IFN plasmid (Supplemental Table 1).
3.3. Adjuvant activity of recombinant IFN with inactivated whole
virus as vaccine
We also tested if recombinant IFNc (rIFNc), might increase the
protective effect of inactivated ISAV as vaccine (WVV) or increase
the humoral immune response against WVV. IFNc was  chosen
because it seemed to be more stable than IFNa in vivo [13] and was
produced in HEK293 cells. Groups of salmon presmolts were vacci-
nated by i.p. injection of WVV  alone, HEK293 medium alone, WVV
and HEK293 medium, rIFNc alone or WVV  and rIFNc, all mixed in
a water in oil emulsion. Eight weeks after vaccination, sera were
harvested and the ﬁsh were challenged with ISAV in a cohabita-
tion infection model. The challenge experiment (Fig. 3A) showed
that the survival of ﬁsh vaccinated with WVV  plus recombinant
IFNc (76%) was higher than ﬁsh vaccinated with WVV  alone (66%)
or WVV  plus HEK293 medium (64%). Fish injected with HEK293
medium alone showed 30% survival. Antibody titers were mea-
sured by ELISA using ISAV as coating antigen (Fig. 3B). Sera from
ﬁsh vaccinated with WVV  alone or WVV  plus HEK293 medium
showed a signiﬁcant increase in antibody titer when compared
to ﬁsh injected with HEK293 medium only (p < 0.05). Sera from
ﬁsh vaccinated with WVV  plus rIFNc showed 3-fold higher titers
(p < 0.01) than the groups vaccinated with WVV  without rIFNc.
Taken together, these results further conﬁrmed the adjuvant activ-
ity of type I IFN in salmon.
3.4. Injection of IFN plasmids increase inﬂux of B cells and CD8
positive cells
The outcome of DNA vaccination is likely to depend on the type
of immune cells that are attracted to the muscle injection site. We
thus measured the change in gene transcripts of various marker
genes for B-cells (IgM, IgT), T-cells (CD3, CD4, CD8) and dendritic
cells (CD83, CD86, MHCII) in the muscle at the injection site of
2446 C.-J. Chang et al. / Vaccine 3
Fig. 3. Survival plots after challenge with ISAV (A) and anti-ISAV antibody responses
(B) of ﬁsh 8 weeks after i.p. injection with vaccines containing inactivated ISAV
(WVV) alone, WVV  and medium from HEK293 cells (HEK), rIFNc alone or WVV  and
recombinant IFNc protein (rIFNc). A. Fish challenged by addition of ISAV infected
cohabitant ﬁsh 8 weeks after vaccination (n = 50). Statistical signiﬁcant differ-
ences were observed between the survival of the HEK group and the WVV  + rIFNc
group (p < 0.0001****), between the HEK group and WVV  group (p < 0.001***) and
between the HEK group and the WVV  + HEK group (p < 0.01**), but not between the
WVV  + rIFNc group and the WVV  or WVV  + HEK groups. B. IgM antibody responses
were tested by ELISA using puriﬁed ISAV as coating antigen (n = 15). Antibody titer
was  determined as the highest dilution whose OD450 was above the mean OD450 plus
2  standard deviations of the same serum dilution from ﬁsh injected with HEK293
cell  supernatant. The ﬁgure shows antibody titers of individuals. Numbers above
columns show mean antibody titers. Statistical signiﬁcant difference was  observed
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observed for the three IFN plasmids, which suggest no increasedetween the WVV  + rIFNc group and the WVV  or WVV  + HEK groups (p < 0.01**).
FNa, IFNb and IFNc plasmids compared to control plasmid and PBS
Fig. 4). The data showed signiﬁcant increases in IgM, IgT and CD8a
or all three IFN plasmids compared to control plasmid (p < 0.05),
hich suggests that IFN expression caused an increased inﬂux of B-
ells and cytotoxic T-cells. Increased transcripts were observed also
or the pan T-cell antigen CD3 for all three pIFNs, while CD4 showed
 minor increase for IFNb and IFNc, but not for pIFNa. Increased
xpression of perforin 1–2 and Granzyme A by the all three IFN
lasmids support that the CD8 positive cells are cytotoxic T-cells.
FNg transcripts were increased only in muscle injected with pIFNa,
owever. The IFN plasmids did not seem to inﬂuence the inﬂux of
endritic cells since there were no or minor increases in transcripts
f CD83, CD86 and MHCII. MHC  I was increased for all three IFN
lasmids. In a separate experiment we observed that injection of
E plasmid did not cause increase in transcription of any of the
enes IgM, CD8a, CD3, CD4, CD83 or CD86, MHCI or MHCII com-
ared to injection of the control plasmid EGFP N1 (Supplemental
ig. 1).3 (2015) 2442–2448
4. Discussion
We  here provide evidence that ﬁsh IFN-I have an important
role in kick-starting the adaptive immune responses against virus.
Strong adjuvant activity of IFNa, IFNb and IFNc plasmids was
observed when injected i.m. together with a plasmid expressing
ISAV HE as antigen, both with respect to protection against ISAV
infection and IgM antibody response against ISAV. I.m. injection of
HE plasmid alone gave some increase in protection as described
in a previous work [12], but far less than in combination with IFN
plasmids. Adjuvant effect was also observed for recombinant IFNc,
which increased the IgM antibody response to inactivated ISAV
upon i.p. delivery. While the adjuvant activity of IFN-I in mammals
has been known previously, the present work shows that the link
between type I IFNs and the adaptive immune system was  estab-
lished in ﬁsh several hundred million years ago. This work supports
that IFN-I may play a role in the protective effect of DNA vaccines
based on VHSV and IHNV G proteins since the latter vaccines are
known to induce IFN-I and IFN-induced genes in the muscle of the
ﬁsh and the VHSV G-protein has been shown to induce IFN-I in cell
culture [20,21].
The protection obtained with IFNa + HE plasmids and IFNb + HE
plasmids must be due to adaptive immune responses since nei-
ther IFNa alone nor IFNb plasmid alone provide any signiﬁcant
protection against ISAV mediated mortality [13]. On the other hand,
the protection obtained with IFNc + HE plasmids is most probably
due both to adaptive and innate immune responses because injec-
tion of IFNc plasmid alone provides a high level of protection against
ISAV infection due to systemic induction of antiviral proteins [13].
The adjuvant effect of IFNc was, however, conﬁrmed by its ability to
enhance the antibody response against ISAV, both when delivered
as gene and as recombinant protein.
The fact that IFNa, IFNb and IFNc all showed similar adjuvant
effects was surprising since they have quite different properties
in Atlantic salmon. The three IFNs are induced through different
signaling pathways and show different expression in cells and tis-
sues [9]. Recent work has shown that salmon IFNa, IFNb and IFNc
utilize different receptors [22]. The immune cells that contribute
to the adjuvant effect of IFN-I in Atlantic salmon must thus have
receptors for all three IFN subtypes since they all show similar adju-
vant properties. Interestingly, the IFNa1 plasmid has been shown to
induces antiviral genes only at the muscle injection site, while the
IFNb and IFNc plasmids induce antiviral genes systemically in the
ﬁsh [13]. This means that the adjuvant effect of the IFNa plasmid is
caused by stimulation of immune cells at the muscle injection site
since IFNa does not induce antiviral genes systemically in salmon.
Accordingly, the adjuvant activity of IFNb and IFNc is also likely to
occur at the muscle injection site. Mammalian studies suggest that
adjuvant activity of IFN-I is pleiotropic and due to direct stimula-
tory effects on T cells, B cells as well as dendritic cells, which are
the main antigen presenting cells [7,23–25]. IFN-I have been shown
to be important for clonal expansion of CD4 and CD8 T-cells and
for initiation of cross-priming of CD8 T cells [26–28]. In addition,
IFN-I have been shown to promote survival of B-cells by inhibi-
tion of apoptosis [29]. The effect of IFN-I on ﬁsh immune cells is
unknown, but the present RT-qPCR studies showed that injection of
all three IFN plasmids caused an increase in transcripts for IgM and
IgT, which suggests an increased inﬂux of B-cells; and an increase
of CD8, perforin and granzyme A transcripts, which suggests an
increased inﬂux of cytotoxic T-cells. This might be explained by
the fact that the IFNs induce several chemokine genes in the muscle
tissue (unpublished data). Increased expression of MHC  II was notattraction of professional antigen presenting cells by IFNs at the
muscle injection site. Antigen presenting cells may  still be involved
in the adjuvant activity of the IFNs since these cells may  be attracted
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Fig. 4. Expression of immune cell marker genes in salmon presmolts after i.m. injection of IFN expression plasmids. Groups of presmolts were injected with PBS, control
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y the wounding caused by injection. The question of whether
uscle cells or professional antigen presenting cells are most
mportant in DNA vaccination mechanism, is still debated [30,31].
The mechanism of protection obtained by injection of IFN plas-
id  together with the HE plasmid is uncertain since the antiserum
rom the vaccinated ﬁsh showed low virus neutralizing activity.
oor ISAV-neutralizing activity was also observed by antiserum
rom Atlantic salmon immunized with a high dose of inactivated
SAV even if the ﬁsh was highly protected against ISAV infection
16]. Non-neutralizing antibodies may  contribute to protection by
ncreased phagocytosis and destruction of virus, but this has yet
o be shown for ﬁsh antibodies. The role of cytotoxic T-cells in the
rotective immune response has to be examined in future studies.
The present demonstration of adjuvant effects of IFN expression
lasmids provides a novel method for improving DNA vaccination
f ﬁsh. This is important since only DNA vaccines against ﬁsh rhab-
ovirus based on the G-protein have until now shown satisfactory
rotection against virus infection. A beneﬁt of DNA vaccines is that
hey induce both humoral and cell mediated adaptive immune
esponses because the protein antigens are produced within the
ost cells [3]. Moreover, they are easy to accommodate to various
irulent virus strains and can be prepared even against viruses that
annot be grown in culture. DNA vaccines are also safe to use and
how less side effects than traditional ﬁsh vaccines, which have to
e delivered in oil adjuvants to give a protective effect.
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[scription was measured by RT-qPCR 7 days after injection, and presented as fold
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